Ascend Capital’s Biogen BIIB Stock Holding History

Ascend Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-75,000	Closed	-$23M	–	107
2015 Q4	$23M	Hold	75,000	–	–	0.81%	39
2015 Q3	$21.9M	Buy	+75,000	New	+$24.8M	0.86%	43

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Ascend Capital's BIIB Position: Q3 2018 in Review

Ascend Capital sold out of Biogen (BIIB) in Q3 2018, closing a stake of 43,945 shares — an estimated $12.8M sold.

Ascend Capital first reported a position in BIIB in Q3 2013 and held it in 13 quarters. The position peaked at $57.9M in Q4 2013. 1,145 funds tracked by Wall St. Rank hold BIIB as of Q3 2018.

Ascend Capital reported no remaining Biogen position as of Q3 2018 after selling out during the quarter.
Ascend Capital sold 43,945 Biogen shares in Q3 2018, an estimated $12.8M.
Ascend Capital first reported a position in Biogen in Q3 2013 and held it in 13 quarters.
Ascend Capital's Biogen position peaked at $57.9M in Q4 2013.
1,145 funds tracked by Wall St. Rank held Biogen as of Q3 2018.

Based on Ascend Capital's 13F filing for Q3 2018, filed 13 Nov 2018.